INTELLIA THERAPEUTICS, INC. Research and Development Expense
INTELLIA THERAPEUTICS, INC. (NTLA) reported Research and Development Expense of $82.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $82.59M, a 14.88% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $80.74M, a 25.54% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $88.65M, a 24.15% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $94.75M, a 23.21% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $388.86M, a 16.61% decline from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $466.31M, a 7.18% increase from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. research and development expense for fiscal 2023 was $435.07M, a 3.59% increase from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. research and development expense for fiscal 2022 was $419.98M, a 82.75% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 8 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $82.59M 10-Q · filed 2026-08-06 | $163.33M 10-Q · filed 2026-08-06 | $251.98M derived: sum of 3 quarters · filed 2026-08-06 | $346.73M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $80.74M 10-Q · filed 2026-05-11 | $169.39M derived: sum of 2 quarters · filed 2026-05-11 | $264.14M derived: sum of 3 quarters · filed 2026-05-11 | $361.17M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $88.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $183.40M derived: sum of 2 quarters · filed 2026-02-26 | $280.43M derived: sum of 3 quarters · filed 2026-08-06 | $388.86M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $94.75M 10-Q · filed 2025-11-06 | $191.78M derived: sum of 2 quarters · filed 2026-08-06 | $300.21M 10-Q · filed 2025-11-06 | $417.09M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $97.03M 10-Q · filed 2026-08-06 | $205.46M 10-Q · filed 2026-08-06 | $322.34M derived: sum of 3 quarters · filed 2026-08-06 | $445.72M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $108.43M 10-Q · filed 2026-05-11 | $225.30M derived: sum of 2 quarters · filed 2026-05-11 | $348.68M derived: sum of 3 quarters · filed 2026-05-11 | $462.89M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $116.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $240.26M derived: sum of 2 quarters · filed 2026-02-26 | $354.46M derived: sum of 3 quarters · filed 2026-02-26 | $466.31M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $123.38M 10-Q · filed 2025-11-06 | $237.59M derived: sum of 2 quarters · filed 2025-11-06 | $349.43M 10-Q · filed 2025-11-06 | $458.42M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $114.21M 10-Q · filed 2025-08-07 | $226.05M 10-Q · filed 2025-08-07 | $335.04M derived: sum of 3 quarters · filed 2026-02-26 | $448.73M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $111.85M 10-Q · filed 2025-05-08 | $220.83M derived: sum of 2 quarters · filed 2026-02-26 | $334.52M derived: sum of 3 quarters · filed 2026-02-26 | $449.80M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $108.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $222.68M derived: sum of 2 quarters · filed 2026-02-26 | $337.95M derived: sum of 3 quarters · filed 2026-02-26 | $435.07M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $113.70M 10-Q · filed 2024-11-07 | $228.97M derived: sum of 2 quarters · filed 2024-11-07 | $326.09M 10-Q · filed 2024-11-07 | $426.12M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $115.28M 10-Q · filed 2024-08-08 | $212.39M 10-Q · filed 2024-08-08 | $312.43M derived: sum of 3 quarters · filed 2025-02-27 | $409.08M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $97.12M 10-Q · filed 2024-05-09 | $197.15M derived: sum of 2 quarters · filed 2025-02-27 | $293.80M derived: sum of 3 quarters · filed 2025-02-27 | $384.00M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $100.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $196.69M derived: sum of 2 quarters · filed 2025-02-27 | $286.88M derived: sum of 3 quarters · filed 2025-02-27 | $419.98M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $96.65M 10-Q · filed 2023-11-09 | $186.85M derived: sum of 2 quarters · filed 2023-11-09 | $319.94M 10-Q · filed 2023-11-09 | $391.11M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | $90.20M 10-Q · filed 2023-08-03 | $223.29M 10-Q · filed 2023-08-03 | $294.45M derived: sum of 3 quarters · filed 2024-02-22 | $354.94M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | $133.09M 10-Q · filed 2023-05-04 | $204.26M derived: sum of 2 quarters · filed 2024-02-22 | $264.74M derived: sum of 3 quarters · filed 2024-02-22 | $323.63M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | $71.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $131.65M derived: sum of 2 quarters · filed 2024-02-22 | $190.53M derived: sum of 3 quarters · filed 2024-02-22 | $229.81M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $60.49M 10-Q · filed 2022-11-03 | $119.37M derived: sum of 2 quarters · filed 2022-11-03 | $158.65M 10-Q · filed 2022-11-03 | $196.88M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $58.88M 10-Q · filed 2022-08-04 | $98.16M 10-Q · filed 2022-08-04 | $136.39M derived: sum of 3 quarters · filed 2022-08-04 | $176.15M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $39.28M 10-Q · filed 2022-05-05 | $77.51M derived: sum of 2 quarters · filed 2022-05-05 | $117.26M derived: sum of 3 quarters · filed 2022-05-05 | $155.03M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $38.23M 10-K · filed 2021-02-26 | $77.99M derived: sum of 2 quarters · filed 2021-11-04 | $115.76M derived: sum of 3 quarters · filed 2021-11-04 | $150.41M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $39.76M 10-Q · filed 2021-11-04 | $77.53M derived: sum of 2 quarters · filed 2021-11-04 | $112.18M 10-Q · filed 2021-11-04 | $143.91M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $37.77M 10-Q · filed 2021-08-05 | $72.42M 10-Q · filed 2021-08-05 | $104.15M derived: sum of 3 quarters · filed 2021-08-05 | $131.66M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $34.65M 10-Q · filed 2021-05-06 | $66.38M derived: sum of 2 quarters · filed 2021-05-06 | $93.89M derived: sum of 3 quarters · filed 2021-05-06 | $119.35M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $31.73M 10-K · filed 2021-02-26 | $59.24M derived: sum of 2 quarters · filed 2021-02-26 | $84.70M derived: sum of 3 quarters · filed 2021-02-26 | $108.41M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $27.51M 10-K · filed 2021-02-26 | $52.97M derived: sum of 2 quarters · filed 2021-02-26 | $76.68M 10-Q · filed 2020-11-05 | $96.60M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-06-30 | $25.46M 10-K · filed 2021-02-26 | $49.17M 10-Q · filed 2020-08-06 | $69.09M derived: sum of 3 quarters · filed 2021-02-26 | $92.32M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-03-31 | $23.71M 10-K · filed 2021-02-26 | $43.63M derived: sum of 2 quarters · filed 2021-02-26 | $66.86M derived: sum of 3 quarters · filed 2021-02-26 | $90.33M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2018-12-31 | $19.92M 10-K · filed 2020-02-27 | $43.16M derived: sum of 2 quarters · filed 2020-02-27 | $66.62M derived: sum of 3 quarters · filed 2020-02-27 | $89.11M 10-K · filed 2021-02-26 | |
| 2018-09-30 | $23.24M 10-K · filed 2020-02-27 | $46.70M derived: sum of 2 quarters · filed 2020-02-27 | $69.20M 10-Q · filed 2019-10-31 | $90.37M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $23.47M 10-K · filed 2020-02-27 | $45.96M 10-Q · filed 2019-08-01 | $67.13M derived: sum of 3 quarters · filed 2020-02-27 | $84.61M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $22.49M 10-K · filed 2020-02-27 | $43.66M derived: sum of 2 quarters · filed 2020-02-27 | $61.14M derived: sum of 3 quarters · filed 2020-02-27 | $76.71M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $21.17M 10-K · filed 2019-02-27 | $38.65M derived: sum of 2 quarters · filed 2019-02-27 | $54.22M derived: sum of 3 quarters · filed 2019-02-27 | $67.65M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $17.48M 10-K · filed 2019-02-27 | $33.05M derived: sum of 2 quarters · filed 2019-02-27 | $46.48M 10-Q · filed 2018-10-31 | $57.81M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $15.56M 10-K · filed 2019-02-27 | $29.00M 10-Q · filed 2018-08-01 | $40.33M derived: sum of 3 quarters · filed 2019-02-27 | $48.19M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $13.43M 10-K · filed 2019-02-27 | $24.76M derived: sum of 2 quarters · filed 2019-02-27 | $32.62M derived: sum of 3 quarters · filed 2019-02-27 | $40.05M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $11.33M 10-K · filed 2018-03-14 | $19.19M derived: sum of 2 quarters · filed 2018-03-14 | $26.61M derived: sum of 3 quarters · filed 2018-03-14 | $31.84M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $7.86M 10-K · filed 2018-03-14 | $15.28M derived: sum of 2 quarters · filed 2018-03-14 | $20.51M 10-Q · filed 2017-10-31 | $24.88M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-06-30 | $7.42M 10-K · filed 2018-03-14 | $12.65M 10-Q · filed 2017-08-01 | $17.02M derived: sum of 3 quarters · filed 2018-03-14 | $20.48M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-03-31 | $5.22M 10-K · filed 2018-03-14 | $9.60M derived: sum of 2 quarters · filed 2018-03-14 | $13.06M derived: sum of 3 quarters · filed 2018-03-14 | $15.02M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2015-12-31 | $4.38M 10-K · filed 2017-03-14 | $7.83M derived: sum of 2 quarters · filed 2017-03-14 | $9.80M derived: sum of 3 quarters · filed 2017-03-14 | $11.17M 10-K · filed 2018-03-14 | |
| 2015-09-30 | $3.46M 10-K · filed 2017-03-14 | $5.42M derived: sum of 2 quarters · filed 2017-03-14 | $6.79M 10-Q · filed 2016-11-01 | ||
| 2015-06-30 | $1.97M 10-K · filed 2017-03-14 | $3.34M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $1.37M 10-K · filed 2017-03-14 | ||||
| 2014-12-31 | $1.10M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |